Limitations, agreements, and source contact

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) · Source last updated 2020-03-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

true

limitations And Caveats

description

The study was terminated due to business decision. No safety concerns involved in decision to terminate this study.

point Of Contact

email

esi_oncmedinfo@eisai.com

organization

Eisai Inc.

phone

1-888-274-2378

title

Eisai Medical Information

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice